Lowering resistin by RNA oligo with reduction of circulating TNF-α and IL-6 might provide a new insight into managing inflammation-mediated diseases, such as NAFLD, type 2 diabetes, and cardiovascular disease. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.